Unicycive Therapeutics (NASDAQ:UNCY) Receives Buy Rating from HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $4.00 target price on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Buy” and an average price target of $5.50.

Unicycive Therapeutics Stock Down 5.4 %

UNCY stock opened at $0.54 on Wednesday. The stock’s 50 day moving average is $0.69 and its 200-day moving average is $0.51. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82. The firm has a market capitalization of $55.95 million, a PE ratio of -0.56 and a beta of 2.30.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UNCY. XTX Topco Ltd purchased a new stake in shares of Unicycive Therapeutics during the third quarter valued at approximately $29,000. Virtu Financial LLC grew its stake in Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after purchasing an additional 62,881 shares during the period. Bleakley Financial Group LLC purchased a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $33,000. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth $807,000. Finally, Walleye Capital LLC purchased a new position in shares of Unicycive Therapeutics in the 3rd quarter worth about $2,040,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.